Last reviewed · How we verify
NCT06856265
Efficacy of Mavacamten Combined With Radiofrequency Ablation in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
NA trial testing radiofrequency ablation in Obstructive Hypertrophic Cardiomyopathy in 40 participants. Not yet recruiting.
1 December 2025
Quick facts
| Lead sponsor | Shanghai Chest Hospital |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 26 February 2025 |
| Primary completion | 1 December 2025 |
| Estimated completion | 1 December 2025 |
Drugs / interventions tested
- radiofrequency ablation
- Mavacamten (MAVACAMTEN) — full drug profile →
Conditions studied
- Obstructive Hypertrophic Cardiomyopathy — all drugs for Obstructive Hypertrophic Cardiomyopathy →
- Mavacamten — all drugs for Mavacamten →
- Radiofrequency Ablation — all drugs for Radiofrequency Ablation →
Sponsor
Shanghai Chest Hospital
Who can join
18 and older, any sex, with Obstructive Hypertrophic Cardiomyopathy or Mavacamten. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to evaluate the efficacy and safety of Mavacamten combined with radiofrequency ablation compared to Mavacamten alone in patients with symptomatic obstructive hypertrophic cardiomyopathy (HOCM). Participants were randomized into two groups:
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Cardiac Myosin Inhibitors (CMIs) and Surgical Referral in Patients with Hypertrophic Cardiomyopathy.
Ferraresi B, Nenna A, Jawabra M, Corrado D, et al · · 2026 · PMID 42188073 · DOI 10.3390/jcdd13050187
Verify or expand the search:
- PubMed search for NCT06856265
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of radiofrequency ablation
Trials testing the same drug.
- NCT07095803 — Ivonescimab (PD-1/VEGF Bispecific Antibody) Plus Radiofrequency Ablation for Multiple Advanced Tumors After PD-1 Therapy · Phase 2 · not yet recruiting
- NCT06984731 — The Safety and Efficacy of Radiofrequency Ablation After Left Atrial Appendage Occlusion. · recruiting
- NCT05738941 — Interventional Radiology in Bony Lesions · unknown
- NCT06798038 — Comparison of the Efficacy of Chemical Genicular Nerve Neurolysis Using Alcohol or Phenol Versus Radiofrequency Ablation · Phase 1 · not yet recruiting
- NCT06355921 — A Prospective Clinical Study on the Safety and Efficacy of Radiofrequency Ablation for the Treatment of Patients With De · NA · not yet recruiting
Other recruiting trials for Obstructive Hypertrophic Cardiomyopathy
Currently open trials in the same condition.
- NCT07023341 — A Study to Learn More About How Well Aficamten Works in Japanese Participants With Symptomatic Obstructive Hypertrophic · Phase 3 · active not recruiting
- NCT06146660 — A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy · recruiting
- NCT06551129 — Real-world Patient Reported Outcomes Among Patients Treated With Camzyos · recruiting
- NCT06023186 — Effect of Mavacamten Treatment on Coronary Flow Reserve in oHCM · recruiting
- NCT05489705 — A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes · recruiting
Other Shanghai Chest Hospital trials
Trials by the same sponsor.
- NCT07515027 — Electroacupuncture Plus 5-HT3 Receptor Inhibitor for PONV Prevention in High-Risk Patients Undergoing Thoracoscopic Lung · NA · recruiting
- NCT07479628 — Neoadjuvant Adebrelimab Plus CRT for Locally Advanced Thymic Carcinoma · Phase 2 · not yet recruiting
- NCT07528066 — Downstaging and RATS After Neo-Chemo-IO: Impact on Surgical Outcomes in NSCLC · recruiting
- NCT07331727 — Epicardial Adipose Tissue-Targeted DApagliflozin for Reducing Electrical Remodeling in Atrial Fibrillation · NA · not yet recruiting
- NCT07320768 — Renal Denervation Combined With Pulsed Field Ablation to Prevent Blanking-Period Recurrence in Persistent Atrial Fibrill · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06856265 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Chest Hospital
- Last refreshed: 4 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06856265.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing